134 related articles for article (PubMed ID: 31434245)
1. Proteomic Phosphosite Analysis Identified Crucial NPM-ALK-Mediated NIPA Serine and Threonine Residues.
Gengenbacher A; Müller-Rudorf A; Poggio T; Gräßel L; Dumit VI; Kreutmair S; Lippert LJ; Duyster J; Illert AL
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31434245
[TBL] [Abstract][Full Text] [Related]
2. Identification and characterization of a nuclear interacting partner of anaplastic lymphoma kinase (NIPA).
Ouyang T; Bai RY; Bassermann F; von Klitzing C; Klumpen S; Miething C; Morris SW; Peschel C; Duyster J
J Biol Chem; 2003 Aug; 278(32):30028-36. PubMed ID: 12748172
[TBL] [Abstract][Full Text] [Related]
3. Extracellular signal-regulated kinase 2 (ERK2) mediates phosphorylation and inactivation of nuclear interaction partner of anaplastic lymphoma kinase (NIPA) at G2/M.
Illert AL; Zech M; Moll C; Albers C; Kreutmair S; Peschel C; Bassermann F; Duyster J
J Biol Chem; 2012 Nov; 287(45):37997-8005. PubMed ID: 22955283
[TBL] [Abstract][Full Text] [Related]
4. NIPA (Nuclear Interaction Partner of ALK) Is Crucial for Effective NPM-ALK Mediated Lymphomagenesis.
Kreutmair S; Lippert LJ; Klingeberg C; Albers-Leischner C; Yacob S; Shlyakhto V; Mueller T; Mueller-Rudorf A; Yu C; Gorantla SP; Miething C; Duyster J; Illert AL
Front Oncol; 2022; 12():875117. PubMed ID: 35646639
[TBL] [Abstract][Full Text] [Related]
5. The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration.
Voena C; Conte C; Ambrogio C; Boeri Erba E; Boccalatte F; Mohammed S; Jensen ON; Palestro G; Inghirami G; Chiarle R
Cancer Res; 2007 May; 67(9):4278-86. PubMed ID: 17483340
[TBL] [Abstract][Full Text] [Related]
6. EBP2, a novel NPM-ALK-interacting protein in the nucleolus, contributes to the proliferation of ALCL cells by regulating tumor suppressor p53.
Uchihara Y; Tago K; Tamura H; Funakoshi-Tago M
Mol Oncol; 2021 Jan; 15(1):167-194. PubMed ID: 33040459
[TBL] [Abstract][Full Text] [Related]
7. Multisite phosphorylation of nuclear interaction partner of ALK (NIPA) at G2/M involves cyclin B1/Cdk1.
Bassermann F; von Klitzing C; Illert AL; Münch S; Morris SW; Pagano M; Peschel C; Duyster J
J Biol Chem; 2007 Jun; 282(22):15965-72. PubMed ID: 17389604
[TBL] [Abstract][Full Text] [Related]
8. NIPA defines an SCF-type mammalian E3 ligase that regulates mitotic entry.
Bassermann F; von Klitzing C; Münch S; Bai RY; Kawaguchi H; Morris SW; Peschel C; Duyster J
Cell; 2005 Jul; 122(1):45-57. PubMed ID: 16009132
[TBL] [Abstract][Full Text] [Related]
9. Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas.
Drexler HG; Gignac SM; von Wasielewski R; Werner M; Dirks WG
Leukemia; 2000 Sep; 14(9):1533-59. PubMed ID: 10994999
[TBL] [Abstract][Full Text] [Related]
10. Serine phosphorylation of NPM-ALK, which is dependent on the auto-activation of the kinase activation loop, contributes to its oncogenic potential.
Wang P; Wu F; Zhang J; McMullen T; Young LC; Ingham RJ; Li L; Lai R
Carcinogenesis; 2011 Feb; 32(2):146-53. PubMed ID: 21045017
[TBL] [Abstract][Full Text] [Related]
11. The tyrosine kinase NPM-ALK, associated with anaplastic large cell lymphoma, binds the intracellular domain of the surface receptor CD30 but is not activated by CD30 stimulation.
Hübinger G; Scheffrahn I; Müller E; Bai R; Duyster J; Morris SW; Schrezenmeier H; Bergmann L
Exp Hematol; 1999 Dec; 27(12):1796-805. PubMed ID: 10641597
[TBL] [Abstract][Full Text] [Related]
12. NPM-ALK mediates phosphorylation of MSH2 at tyrosine 238, creating a functional deficiency in MSH2 and the loss of mismatch repair.
Bone KM; Wang P; Wu F; Wu C; Li L; Bacani JT; Andrew SE; Lai R
Blood Cancer J; 2015 May; 5(5):e311. PubMed ID: 25978431
[TBL] [Abstract][Full Text] [Related]
13. NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a.
Gu TL; Tothova Z; Scheijen B; Griffin JD; Gilliland DG; Sternberg DW
Blood; 2004 Jun; 103(12):4622-9. PubMed ID: 14962911
[TBL] [Abstract][Full Text] [Related]
14. The tyrosine 343 residue of nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) is important for its interaction with SHP1, a cytoplasmic tyrosine phosphatase with tumor suppressor functions.
Hegazy SA; Wang P; Anand M; Ingham RJ; Gelebart P; Lai R
J Biol Chem; 2010 Jun; 285(26):19813-20. PubMed ID: 20424160
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
[TBL] [Abstract][Full Text] [Related]
16. Disheveled proteins promote cell growth and tumorigenicity in ALK-positive anaplastic large cell lymphoma.
Hegazy SA; Alshareef A; Gelebart P; Anand M; Armanious H; Ingham RJ; Lai R
Cell Signal; 2013 Jan; 25(1):295-307. PubMed ID: 23022960
[TBL] [Abstract][Full Text] [Related]
17. Analysis of gene expression profile of TPM3-ALK positive anaplastic large cell lymphoma reveals overlapping and unique patterns with that of NPM-ALK positive anaplastic large cell lymphoma.
Bohling SD; Jenson SD; Crockett DK; Schumacher JA; Elenitoba-Johnson KS; Lim MS
Leuk Res; 2008 Mar; 32(3):383-93. PubMed ID: 17720243
[TBL] [Abstract][Full Text] [Related]
18. Silibinin suppresses NPM-ALK, potently induces apoptosis and enhances chemosensitivity in ALK-positive anaplastic large cell lymphoma.
Molavi O; Samadi N; Wu C; Lavasanifar A; Lai R
Leuk Lymphoma; 2016 May; 57(5):1154-62. PubMed ID: 26133723
[TBL] [Abstract][Full Text] [Related]
19. Identification of a novel crosstalk between casein kinase 2α and NPM-ALK in ALK-positive anaplastic large cell lymphoma.
Armanious H; Gelebart P; Anand M; Lai R
Cell Signal; 2013 Feb; 25(2):381-8. PubMed ID: 23153582
[TBL] [Abstract][Full Text] [Related]
20. Expression of the oncogenic NPM-ALK chimeric protein in human lymphoid T-cells inhibits drug-induced, but not Fas-induced apoptosis.
Greenland C; Touriol C; Chevillard G; Morris SW; Bai R; Duyster J; Delsol G; Allouche M
Oncogene; 2001 Nov; 20(50):7386-97. PubMed ID: 11704868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
